Skip to main contentLast updated: 17-Nov-2026
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Stomach Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
A GIST is a tumour driven by one faulty switch inside its cells. Most often the switch is a gene called KIT. Less often it is PDGFRA, or the SDH group of genes.
Which gene is at fault, and where, decides the tablet, the dose and how long you need it. One result, PDGFRA D842V, means the usual tablet imatinib will not work.
So the gene report is not a formality. Ask for it in every GIST that is large, high risk or has spread.
For the whole story of GIST, from the first test to imatinib and surgery, read our GIST treatment in Ahmedabad page. This post explains what your pathology and gene report actually says.
A GIST starts from the interstitial cells of Cajal. These are the gut’s pacemaker cells, which set the rhythm of the muscle wall that moves food along.
Where these tumours sit, and how common they are, is covered in our post on how common GIST is and what types exist.
The pathologist describes the shape of the cells, counts how many are dividing, and notes whether the tumour was intact when removed. Each of these changes the plan.
Size, the dividing-cell count and the site together give the risk group. Our post on how surgery and imatinib are put in order shows how that group guides the tablets.
Two stains matter most, KIT (also called CD117) and DOG1. Used together with the clinical picture, they settle the diagnosis in nearly every case.
A tumour that looks like a GIST on the scan can turn out to be something else. This is why the stains are read together, and why a biopsy is not skipped. Our post on how a GIST is confirmed with CT, scope and biopsy covers how the sample is taken.
The gene result tells us which medicine the tumour will respond to. This is the part of the report that changes treatment the most.
| Gene result | How the tumour tends to behave | What it means for treatment |
|---|---|---|
| KIT exon 11 (the commonest KIT change) | Responds well to imatinib; a deletion at one spot, codons 557 and 558, tends to return sooner | Usual imatinib dose; tablets after surgery are strongly considered when a deletion is found |
| KIT exon 9 | Seen more in the small bowel; imatinib works but needs more | A higher imatinib dose when the disease has spread |
| KIT exon 13 or 17 | Uncommon; the tablet may work only in part or stop working early | Later medicines such as sunitinib may be needed sooner |
| PDGFRA, not D842V | Usually in the stomach, often slow growing | Imatinib works; used if the risk group calls for it |
| PDGFRA D842V | Usually in the stomach, often slow growing | Imatinib does not work; avapritinib is used if medicine is needed |
| SDH-deficient (no KIT or PDGFRA change) | Younger patients, stomach, often several lumps; may reach lymph glands | Imatinib helps little; surgery and careful watching come first |
The table is a guide to the pattern, not a promise for any one person. Your own result is read together with the size, site and risk group of your tumour.
Because the usual tablet cannot grip this change. Giving imatinib for it only loses time, so the gene report must be in hand before the tablet is chosen.
Our post on the key GIST studies and what is new sets out the research behind avapritinib.
It is a different disease that looks like a GIST. The tumour has lost a part of the cell’s energy machinery, called SDH, and it behaves in its own way.
A lost SDHB stain can point to a family condition. A rare pattern, Carney triad, joins a stomach GIST to a lung growth and a tumour near the nerves. When SDH is lost, a genetics doctor checks whether the change was inherited, and relatives may be offered checks.
A small group of GISTs have none of these. A wider gene panel is then sent, because a few of these rare changes have a medicine made for them.
This is why a first report that says only “KIT-positive” is not the end. It tells you the stain was positive. It does not tell you the gene change.
The wax-embedded block from the biopsy or from the operation is sent to a reference laboratory. The minimum test reads the main parts of KIT and PDGFRA.
Laboratories in India, including large cancer centres, run these panels. The result usually takes a couple of weeks, and the wider panel a little longer, so the sample is sent early and not left until the day tablets are due.
Four questions cover it. Ask them at your next visit, with the report in hand.
If any answer is missing, the report is not yet complete. Dr Shah will go through it with you and order what is missing.
It reads the tumour's DNA to find which switch is stuck on, most often KIT or PDGFRA. The answer tells the team which tablet will work and at what dose.
Not every one. It is a must when the disease has spread, and when a tumour is large or high risk and tablets are planned. A very small, low-risk tumour may not need it.
No. KIT-positive is a stain on the slide. It confirms the type of tumour. The gene result is a separate test that names the exact change.
This change keeps the target in a shape the tablet cannot bind. Imatinib would not slow the tumour, so a different medicine, avapritinib, is used if medicine is needed.
The tumour has lost part of the cell's energy machinery. It is seen in younger people, sits in the stomach, may spread to lymph glands and responds poorly to imatinib.
Rarely. Most are not inherited. A GIST with lost SDH, or with NF1, can be part of a family condition, so a genetics doctor may check and relatives may be offered tests.
A wider gene panel is sent. It looks for SDH loss, NF1, NTRK and BRAF changes. Some of these have a medicine made for them, and a trial may also be an option.
For the full picture of GIST and its treatment, start at the GIST treatment in Ahmedabad page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Handed a GIST report full of terms like KIT, exon 11, PDGFRA or SDH, and not sure what they mean for you? These words are not just labels. They tell the team which medicine will work, which will not, and how closely you need to be watched. Dr Harsh Shah, a stomach cancer surgeon in Ahmedabad, reads your pathology and gene report with you in plain words. Bring the report along. You can call us or book by message. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.